Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Speyer, Cecilia L ^a   Hachem, Ali H ^b   Assi, Ali A ^b   Johnson, Jennifer S ^c   DeVries, John A ^a   Gorski, David H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN DEARBORN   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BAY 36 7620; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR ANTAGONIST; RILUZOLE; SHORT HAIRPIN RNA; SUNITINIB; UNCLASSIFIED DRUG; YM 298198; 6-AMINO-N-CYCLOHEXYL-N,3-DIMETHYLTHIAZOLO(3,2-A)BENZIMIDAZOLE-2-CARBOXAMIDE; BAY36-7620; BENZIMIDAZOLE DERIVATIVE; METABOTROPIC GLUTAMATE RECEPTOR TYPE 1; METABOTROPIC RECEPTOR; NAPHTHALENE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; GRM1 GENE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST TUMOR; CELL LINE; DRUG EFFECTS; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM;

ANIMALS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL LINE; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NAPHTHALENES; RECEPTORS, METABOTROPIC GLUTAMATE; THIAZOLES;

EID: 84898426663     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088830     Document Type: Article

References (55)

1. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
2. Folkman J (2001) Angiogenesis-dependent diseases. Semin Oncol 28: 536-542.
3. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410. (Pubitemid 37328844)
4. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364. (Pubitemid 26272076)
5. Greenberg JI, Cheresh DA (2009) VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 9: 1347-1356.
6. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, et al. (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80: 1945-1953. (Pubitemid 27479789)
7. Weidner N, Folkman J (1996) Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol: 167-190.
8. Weidner N (1998) Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 184: 119-122.
9. Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704.
10. Higa GM, Abraham J (2009) Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther 9: 999-1007.
11. Hsu JY, Wakelee HA (2009) Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23: 289-304.
12. Takahashi T, Ueno H, Shibuya M (1999) VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18: 2221-2230. (Pubitemid 29186923)
13. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, et al. (1996) Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98: 2018-2026. (Pubitemid 26376289)
14. Noh KM, Hwang JY, Shin HC, Koh JY (2000) A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiol Dis 7: 375-383.
15. Yoo MH, Hyun HJ, Koh JY, Yoon YH (2005) Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Invest Ophthalmol Vis Sci 46: 4780-4787. (Pubitemid 44264584)
16. Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, et al. (2010) The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 130: 2240-2249.
17. Namkoong J, Shin SS, Lee HJ, Marin YE, Wall BA, et al. (2007) Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67: 2298-2305. (Pubitemid 46424250)
18. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34: 1-26.
19. Francesconi A, Duvoisin RM (1998) Role of the second and third intracellular loops of metabotropic glutamate receptors in mediating dual signal transduction activation. J Biol Chem 273: 5615-5624. (Pubitemid 28124031)
20. Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22: 368-376. (Pubitemid 32592476)
21. Wang JQ, Tang Q, Parelkar NK, Liu Z, Samdani S, et al. (2004) Glutamate signaling to Ras-MAPK in striatal neurons: mechanisms for inducible gene expression and plasticity. Mol Neurobiol 29: 1-14. (Pubitemid 39118075)
22. Waters C, Pyne S, Pyne NJ (2004) The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Semin Cell Dev Biol 15: 309-323. (Pubitemid 38581999)
23. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, et al. (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21: 1013-1033. (Pubitemid 32823739)
24. Festoff BW (1996) Amyotrophic lateral sclerosis: current and future treatment strategies. Drugs 51: 28-44.
25. Mills CD, Johnson KM, Hulsebosch CE (2002) Group I metabotropic glutamate receptors in spinal cord injury: roles in neuroprotection and the development of chronic central pain. J Neurotrauma 19: 23-42. (Pubitemid 34117094)
26. Niswender CM, Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50: 295-322.
27. Gladding CM, Fitzjohn SM, Molnar E (2009) Metabotropic glutamate receptor-mediated long-term depression: molecular mechanisms. Pharmacol Rev 61: 395-412.
28. Bonsi P, Cuomo D, De Persis C, Centonze D, Bernardi G, et al. (2005) Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons. Neuropharmacology 49 Suppl 1: 104-113. (Pubitemid 41115897)
29. Chu Z, Hablitz JJ (2000) Quisqualate induces an inward current via mGluR activation in neocortical pyramidal neurons. Brain Res 879: 88-92.
30. Endoh T (2004) Characterization of modulatory effects of postsynaptic metabotropic glutamate receptors on calcium currents in rat nucleus tractus solitarius. Brain Res 1024: 212-224.
31. Gerber U, Gee CE, Benquet P (2007) Metabotropic glutamate receptors: intracellular signaling pathways. Curr Opin Pharmacol 7: 56-61. (Pubitemid 46238032)
32. Chavis P, Fagni L, Lansman JB, Bockaert J (1996) Functional coupling between ryanodine receptors and L-type calcium channels in neurons. Nature 382: 719-722. (Pubitemid 26282178)
33. Mao L, Wang JQ (2003) Group I metabotropic glutamate receptor-mediated calcium signalling and immediate early gene expression in cultured rat striatal neurons. Eur J Neurosci 17: 741-750. (Pubitemid 36315244)
34. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, et al. (2011) Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 60: 1017-1041.
35. O'Riordan KJ, Huang IC, Pizzi M, Spano P, Boroni F, et al. (2006) Regulation of nuclear factor kappaB in the hippocampus by group I metabotropic glutamate receptors. J Neurosci 26: 4870-4879. (Pubitemid 44315328)
36. Collard CD, Park KA, Montalto MC, Alapati S, Buras JA, et al. (2002) Neutrophil-derived glutamate regulates vascular endothelial barrier function. J Biol Chem 277; 14801-14811. (Pubitemid 34952552)
37. Lin SH, Maiese K (2001) Group I metabotropic glutamate receptors prevent endothelial programmed cell death independent from MAP kinase p38 activation in rat. Neurosci Lett 298: 207-211.
38. Speyer CL, Smith JS, Banda M, Devries JA, Mekani T, et al. (2011) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132(2):565-73.
39. Patel S, Leal AD, Gorski DH (2005) The homeobox gene Gax inhibits angiogenesis through inhibition of nuclear factor-kappaB-dependent endothelial cell gene expression. Cancer Res 65: 1414-1424. (Pubitemid 40270170)
40. Nor JE, Peters MC, Christensen JB, Sutorik MM, Linn S, et al. (2001) Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 81: 453-463. (Pubitemid 32298790)
41. Kohara A, Toya T, Tamura S, Watabiki T, Nagakura Y, et al. (2005) Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1. J Pharmacol Exp Ther 315: 163-169. (Pubitemid 41380509)
42. Mabire D, Coupa S, Adelinet C, Poncelet A, Simonnet Y, et al. (2005) Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists. J Med Chem 48: 2134-2153. (Pubitemid 40396342)
43. Zona C, Siniscalchi A, Mercuri NB, Bernardi G (1998) Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience 85: 931-938. (Pubitemid 28223653)
44. Miller RG, Mitchell JD, Lyon M, Moore DH (2003) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 4: 191-206. (Pubitemid 37184890)
45. Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, et al. (2009) Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 8: 1761-1771.
46. Tao K, Fang M, Alroy J, Sahagian GG (2008) Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 8: 228.
47. Hebert T, Drapeau P, Pradier L, Dunn RJ (1994) Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 45: 1055-1060. (Pubitemid 24155800)
48. Marin YE, Namkoong J, Cohen-Solal K, Shin SS, Martino JJ, et al. (2006) Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal 18: 1279-1286. (Pubitemid 43674044)
49. Harris SL, Cho K, Bashir ZI, Molnar E (2004) Metabotropic glutamate receptor signalling in perirhinal cortical neurons. Mol Cell Neurosci 25: 275-287. (Pubitemid 38338639)
50. Hou L, Klann E (2004) Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci 24: 6352-6361. (Pubitemid 38944226)
51. Liu F, Virshup DM, Nairn AC, Greengard P (2002) Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors. J Biol Chem 277: 45393-45399. (Pubitemid 36159147)
52. Ribeiro FM, Pires RG, Ferguson SS (2011) Huntington's disease and Group I metabotropic glutamate receptors. Mol Neurobiol 43: 1-11.
53. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, et al. (1998) Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58: 5686-5689. (Pubitemid 29006406)
54. Miller FR (1983) Tumor subpopulation interactions in metastasis. Invasion Metastasis 3: 234-242.
55. Miller FR, Miller BE, Heppner GH (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3: 22-31. (Pubitemid 13083351)